Colorectal Cancer Epigenetics: From Bench to Bedside
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Epigenetic Therapy".
Deadline for manuscript submissions: closed (1 July 2023) | Viewed by 225
Special Issue Editors
Interests: surgery; transplantation; surgical oncology; oncology; experimental surgery
Special Issues, Collections and Topics in MDPI journals
Interests: surgery; hepatocellular carcinoma; targeted therapies
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
[*] Background & history of this topic:
Colorectal cancer (CRC) is a significant health problem, being the third-most-common cancer and the third-leading cause of cancer-related deaths, in both men and women. The incidence of CRC differs by race and ethnicity and is more common in people over 65 years old than in those under 45. Family history can increase the risk of CRC, as can various lifestyle factors. In addition to environmental influences, genetic and epigenetic factors also contribute to the development of CRC. Environmental risk factors can lead to genetic and epigenetic changes in colorectal cells, which, combined with an individual's inherited genetic makeup, may result in tumor growth. Epigenetic factors also play a role in the progression of CRC, which is not only driven by genomic and genetic changes, such as gene mutations and deletions, but also by epigenetic changes. Despite the best understanding of the involved pathways, it is well established that HCC is a highly resistant malignancy to the existing therapeutic strategies. As a result, in the presison medicine era, the interest of treating CRC is to clarify the signal pathways and the genes related to carcinogenesis, as well as to chemotherapy resistance.
[*] Aim and scope of the Special Issue:
The aim of this Special Issue is to reveal innovative findings and concepts covering the entire spectrum, from pathogenesis to treatment of CRC in the era of precision medicine.
[*] Cutting-edge research:
Gene mutations; DNA alterations; targeted therapy; immunotherapy.
[*] What kind of papers we are soliciting:
Review, original studies, case reports, opinion articles.
Dr. Christos Damaskos
Dr. Nikolaos Garmpis
Dr. Christos Doudakmanis
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- colorectal cancer
- molecular background
- targeted therapy
- immunotherapy
- precision medicine
